Antistaphylococcal vaccines and immunoglobulins: current status and future prospects.
Staphylococci are among the most frequently encountered pathogens in both the inpatient and the outpatient setting. Management of infections caused by these organisms is complicated by the increasingly common resistance of staphylococcal pathogens to commonly used antibacterials. As a consequence, novel approaches to prevention and treatment are urgently required. Such approaches include the development of vaccines and immunoglobulin preparations targeted at virulence factors expressed in vivo by staphylococci. This article reviews the biopharmaceutical progress made to date in this field and suggests approaches to further progress.
Deresinski
Stan
S
Stanford University, Stanford, California, USA. polishmd@stanford.edu
D000907:Antibodies, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D013203:Staphylococcal Infections / Q000276:immunology / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014611:Vaccination; D037521:Virulence Factors
D000907:Antibodies, Bacterial; D013209:Staphylococcal Vaccines; D037521:Virulence Factors